Cargando…

[(123)I]CC1: A PARP-Targeting, Auger Electron–Emitting Radiopharmaceutical for Radionuclide Therapy of Cancer

Poly(adenosine diphosphate ribose) polymerase (PARP) has emerged as an effective therapeutic strategy against cancer that targets the DNA damage repair enzyme. PARP-targeting compounds radiolabeled with an Auger electron–emitting radionuclide can be trapped close to damaged DNA in tumor tissue, wher...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chan, Chung Ying, Chen, Zijun, Guibbal, Florian, Dias, Gemma, Destro, Gianluca, O’Neill, Edward, Veal, Mathew, Lau, Doreen, Mosley, Michael, Wilson, Thomas C., Gouverneur, Véronique, Cornelissen, Bart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society of Nuclear Medicine 2023
Materias:	Basic Science Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690119/ https://www.ncbi.nlm.nih.gov/pubmed/37770109 http://dx.doi.org/10.2967/jnumed.123.265429

Ejemplares similares

Imaging PARP with [(18)F]rucaparib in pancreatic cancer models
por: Chan, Chung Ying, et al.
Publicado: (2022)

Preclinical Efficacy of a PARP-1 Targeted Auger-Emitting Radionuclide in Prostate Cancer
por: Sreekumar, Sreeja, et al.
Publicado: (2023)

Correlation between molar activity, injection mass and uptake of the PARP targeting radiotracer [(18)F]olaparib in mouse models of glioma
por: Chan, Chung Ying, et al.
Publicado: (2022)

Evaluation of Acridine Orange Derivatives as DNA-Targeted Radiopharmaceuticals for Auger Therapy: Influence of the Radionuclide and Distance to DNA
por: Pereira, Edgar, et al.
Publicado: (2017)

[(18)F]AZD2461, an Insight on Difference in PARP Binding Profiles for DNA Damage Response PET Imaging
por: Guibbal, Florian, et al.
Publicado: (2020)

Application of Geant4-DNA for simulating water radiolysis induced by Auger electron-emitting radionuclides
por: Adjei, Daniel, et al.
Publicado: (2023)

Heterogeneity of dose distribution in normal tissues in case of radiopharmaceutical therapy with alpha-emitting radionuclides
por: Li, Wei Bo, et al.
Publicado: (2022)

Nanostructures as Radionuclide Carriers in Auger Electron Therapy
por: Gharibkandi, Nasrin Abbasi, et al.
Publicado: (2022)

Radiofluorination of a highly potent ATM inhibitor as a potential PET imaging agent
por: Fraser, Claudia Rose, et al.
Publicado: (2022)

Targeted Auger electron-emitter therapy: Radiochemical approaches for thallium-201 radiopharmaceuticals
por: Rigby, Alex, et al.
Publicado: (2021)

Targeted Radionuclide Therapy Using Auger Electron Emitters: The Quest for the Right Vector and the Right Radionuclide
por: Idrissou, Malick Bio, et al.
Publicado: (2021)

Novel diagnostic and therapeutic radionuclides for the development of innovative radiopharmaceuticals
por: Airaksinen, A, et al.
Publicado: (2016)

Radiopharmaceuticals and other compounds labelled with short-lived radionuclides
por: Welch, Michael J
Publicado: (2013)

Novel diagnostic and therapeutic radionuclides for the development of innovative radiopharmaceuticals
por: Domnanich, Katharina, et al.
Publicado: (2014)

Novel diagnostic and therapeutic radionuclides for the development of innovative radiopharmaceuticals
por: Dorrer, H, et al.
Publicado: (2011)

Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals()
por: Cai, Zhengxin, et al.
Publicado: (2013)

(188)Re(V) Nitrido Radiopharmaceuticals for Radionuclide Therapy
por: Boschi, Alessandra, et al.
Publicado: (2017)

(111)In-BnDTPA-F3: an Auger electron-emitting radiotherapeutic agent that targets nucleolin
por: Cornelissen, Bart, et al.
Publicado: (2012)

IS528 Novel diagnostic and therapeutic radionuclides for the development of innovative radiopharmaceuticals
por: Koester, Ulli, et al.
Publicado: (2018)

IS528 Novel diagnostic and therapeutic radionuclides for the development of innovative radiopharmaceuticals
por: Köster, Ulli
Publicado: (2017)

Radiopharmaceutical Treatments for Cancer Therapy, Radionuclides Characteristics, Applications, and Challenges
por: Salih, Suliman, et al.
Publicado: (2022)

Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen in a micrometastatic model of prostate cancer
por: Shen, Colette J., et al.
Publicado: (2020)

Combination Strategies to Improve Targeted Radionuclide Therapy
por: Chan, Tiffany G., et al.
Publicado: (2020)

In vitro cytotoxicity of Auger electron-emitting [(67)Ga]Ga-trastuzumab
por: Othman, Muhamad Faiz bin, et al.
Publicado: (2020)

Internal microdosimetry of alpha-emitting radionuclides
por: Hofmann, Werner, et al.
Publicado: (2019)

EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides
por: Handkiewicz-Junak, Daria, et al.
Publicado: (2018)

Development and optimization of targeted radionuclide tumor therapy using folate based radiopharmaceuticals
por: Reber, Josefine Astrid
Publicado: (2015)

Lutathera(®): The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
por: Hennrich, Ute, et al.
Publicado: (2019)

The Chemical Scaffold of Theranostic Radiopharmaceuticals: Radionuclide, Bifunctional Chelator, and Pharmacokinetics Modifying Linker
por: Holik, Holis Abdul, et al.
Publicado: (2022)

Controlling the influence of Auger recombination on the performance of quantum-dot light-emitting diodes
por: Bae, Wan Ki, et al.
Publicado: (2013)

Bioaccumulation of gamma emitting radionuclides in Polysiphonia fucoides
por: Zalewska, Tamara
Publicado: (2013)

Reducing the impact of Auger recombination in quasi-2D perovskite light-emitting diodes
por: Jiang, Yuanzhi, et al.
Publicado: (2021)

Closing the gap between (19)F and (18)F chemistry
por: Ajenjo, Javier, et al.
Publicado: (2021)

Correction to: Closing the gap between (19)F and (18)F chemistry
por: Ajenjo, Javier, et al.
Publicado: (2022)

PET Imaging of PARP Expression Using (18)F-Olaparib
por: Wilson, Thomas C., et al.
Publicado: (2019)

Palmitic Acid-Conjugated Radiopharmaceutical for Integrin α(v)β(3)-Targeted Radionuclide Therapy
por: Yang, Guangjie, et al.
Publicado: (2022)

PARP targeted Auger emitter therapy with [(125)I]PARPi-01 for triple-negative breast cancer
por: Ambur Sankaranarayanan, Ramya, et al.
Publicado: (2022)

Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
por: Nonnekens, Julie, et al.
Publicado: (2016)

Spectro Auger
Publicado: (1995)

In Vitro Evaluation of No-Carrier-Added Radiolabeled Cisplatin ([(189, 191)Pt]cisplatin) Emitting Auger Electrons
por: Obata, Honoka, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5k4bhg1lnrktclv593rlf9bsdv